Asian Spectator


The Times

.

Celosia Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of CTx1000 in Amyotrophic Lateral Sclerosis

  • Written by PR Newswire Asia - Asian Spectator

CTx1000 designed to clear pathological TDP-43 protein, a central driver of ALS

SYDNEY, March 24, 2026 /PRNewswire/ -- Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, today announced dosing of the first participant in its Phase 1b KOANEWA trial evaluating CTx1000, an...

Magazine

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

Compressed Air Pipe and Fittings: What Every Australian Industrial Facility Needs to Know

Compressed air is the fourth utility of modern industry, right alongside electricity, gas, and water. Yet despite its critical role in powering everything from pneumatic tools to automated productio...

Common Risks Hidden in Commercial Lease Agreements

Commercial leases are often longer and more complex than tenants expect, and the fine print can carry significant financial and operational consequences over the years that follow. Many business own...

hacklink hack forum hacklink film izle hacklink z-libraryzlibrary bookscasino en ligneWPS下载IND RUMMYnon gamstop casinosnon gamstop casinos uknon gamstop casinoscasinos not on gamstopcasinos not on gamstopnon gamstop casinoonline gamblinguk casinosuk casinosStreamEastStreamEastcasibom girişmeritkingcashnow.imweb.mejojobetcasibomholiganbetmarsbahismarsbahis girişmarsbahis güncel girişnakitbahis girişnakitbahis girişmatbet girişjojobet